Clene’s (CLNN) cash, cash equivalents and marketable securities totaled $12.2 million as of December 31, 2024, compared to $35.0 million as of December 31, 2023. Clene expects that its resources as of December 31, 2024, will be sufficient to fund its operations into the second quarter of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Promising Potential of Clene’s CNM-Au8 for ALS Drives Buy Rating
- Clene announces evidence from post-hoc analysis of HEALY ALS platform trial
- Strategic Advancements and Regulatory Progress Bolster Clene’s ALS Treatment Outlook
- Clene, ASPT Research enter agreement to utilize NfL database for CNM-Au8
- Clene files to sell 1.15M shares of common stock for holders